all report title image
  • Published On : Nov 2022
  • Code : CMI1728
  • Industry : Biotechnology
  • Pages : 205
  • Formats :

Cellular therapy is the transplantation of human cells to replace or repair damaged tissue or cells. Numerous different types of cells may be used as part of a therapy or treatment for a number of diseases and disorders with the help of new technologies, inventive products, and infinite imagination. Hematopoietic (blood-forming) stem cells (HSC), skeletal muscle stem cells, mesenchymal stem cells, lymphocytes, dendritic cells, and pancreatic islet cells are a few of the cells that could be used.

Global cell therapy manufacturing market is estimated to be valued at US$ 3,755.4 million in 2022 and is expected to exhibit a CAGR of 15.2% during the forecast period (2022-2030).

Figure 1. Global Cell Therapy Manufacturing Market Share (%), by Application, 2022

Cell Therapy Manufacturing  | Coherent Market Insights

Global Cell Therapy Manufacturing Market- Drivers

Manufacturers are involved in developing and launching various types of technologies for cell therapy manufacturing, which is expected to propel the growth of global cell therapy manufacturing market. For instance, in July 2022, INVETECH, a global company offering solutions, systems, and services to cell and gene therapy, announced the launch of new korus technology for autologous cell therapy production. Korus is a closed system for the production of autologous cell therapy. Providing elutriation and cell washing using gentle counterflow centrifugation to remove contaminants and produce a purified population of target cells.

Manufacturers of cell therapy product are in receiving regulatory approvals to enhance their cell therapy manufacturing process, which in turn is expected to drive the global cell therapy manufacturing market growth. For instance, in May 2022, the U.S. Food and Drug Administration announced that it had approved Novartis’s chimeric antigen receptor (CAR) T-cell therapy Kymriah, for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

CMI table icon

Cell Therapy Manufacturing Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 3,755.4 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 15.2% 2030 Value Projection: US$ 11,633.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Therapy Type: Allogeneic Cell Therapy Autologous Cell Therapy 
  • By Technology Type: Somatic Cell Technology, Cell Immortalization Technology, Viral Vector Technology, Genome Editing Technology, Cell Plasticity Technology, 3D Technology
  • By Source: IPSC’s (Induced pluripotent stem cell), Bone Marrow, Umbilical Cord, Adipose Tissue, Neural Stem
  • By Application: Musculoskeletal, Cardiovascular, Gastrointestinal, Neurological, Oncology, Dermatology, Others
Companies covered:

WuXi AppTec, Inc., Lineage Cell Therapeutics, Inc., HEALIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc.

Growth Drivers:
  • Increasing collaborations by key market players
  • Increasing development and launching various types of technologies for cell therapy manufacturing
  • Increasing cell therapy based research and development 
Restraints & Challenges:
  • High cost of cell and gene therapies

Figure 2. Global Cell Therapy Manufacturing Market Share (%), by Region, 2022

Cell Therapy Manufacturing  | Coherent Market Insights

Global Cell Therapy Manufacturing Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of medical devices, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Players operating in the global cell therapy manufacturing market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials due to irregularities in transportation facility. Furthermore, distributors are experiencing irregular demand for products from the retailers due to rising incidence of COVID -19.

However, there has been a slight positive impact on market as cell therapies are under research for the treatment of COVID-19. For instance, According to an research published on February 20, 2022, by the Springer Nature, mesenchymal cells (MSCs) are currently been studied as one of the treatment methods to treat COVID-19 disease. Researchers use immunosuppressive drugs (Tocilizumab) to alleviate COVID-19 symptoms in patients, these cells, due to their mechanism of action, can significantly improve critical conditions. Use of MSCs has shown positive effects for the treatment of COVID-19 as these cells can modulate the immune system.

Global Cell Therapy Manufacturing Market: Key Developments

In May 2020, WuXi Advanced Therapies, a contract development and manufacturing organization (CDMO) of WuXi AppTec., a Pharmaceutical company, announced that it had expanded its service capabilities to offer a fully integrated, closedprocess CAR-T cell therapy platform. This new platform will shorten the timeframe for developing, manufacturing, and delivering cell and gene therapies while providing better predictability.

Global Cell Therapy Manufacturing Market: Restraint

High cost of cell therapies is one of the biggest challenges, with financial implications for patients, payers, and providers, which is expected to hamper the market growth over the forecast period. For instance, in May 2022, chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) received the U.S. FDA approval for the treatment of pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) and it costs around US$ 475,000 for a single infusion. This has resulted in limited adoption of such therapies, thereby hampering growth of the market. Moreover, in April 2022, Yescarta, a cell therapy was approved by the U.S. FDA for the treatment of certain B-cell lymphomas. The listed price for axicabtagene ciloleucel (Yescarta) in the U.S. is US$ 373,000.

Global Cell Therapy Manufacturing Market- Key Players

Major players operating in the global cell therapy manufacturing market include Wuxi AppTec, Inc, Lineage Cell Therapeutics, Inc., HEALIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc.

Cellular treatment uses living cells to kill and regulate cancer cells. Cellular therapy, according to researcher, uses the cell itself as medicine, in place of pharmaceuticals. As an illustrative example, adoptive T-cell transfer, also known as adoptive cell therapy, is a procedure that involves removing cancer-killing T cells from the patient's blood, boosting their number in a lab, and then reintroducing them to the patient to bolster the immune system's fight against the illness.

The cell therapy market is expected to gain further traction, with evolving treatment options and rapid technological innovation in cell therapy. Fewer side effects, high effectiveness and potent action, and ability to cure the disease are some of the major advantages of cell therapy. Roswell Park, a cancer treatment center, treats specific types of leukemia and lymphoma with Kymriah (tisagenlecleucel), Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel), and to treat multiple myeloma with Abecma (idecabtagene vicleucel). Cellular therapies may also be available through clinical trials for the treatment of Metastatic melanoma, Multiple myeloma, Neuroblastoma and synovial cell carcinoma, ovarian cancer, etc.

Market Dynamics

The increasing government initiatives for the advancement in the manufacturing of cell therapy is expected to fuel the market growth over the forecast period. For instance, on February 15, 2022, Brainstorm Cell Therapeutics Inc., a developer of adult stem cell therapeutics for neurodegenerative diseases, announced that the Brazilian Patent Office approved a patent Technology Type titled "A method of generating cells which secrete Brain Derived Neurotrophic Factor (BDNF), Glial Derived Neurotrophic Factor (GDNF), Hepatocyte Growth Factor (HGF) and Vascular Endothelial Growth Factor (VEGF), wherein said cells do not Secrete Nerve Growth Factor (NGF)".

Key features of the study:

  • This report provides an in-depth analysis of the global cell therapy manufacturing market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global cell therapy manufacturing market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include WuXi AppTec, Inc., Lineage Cell Therapeutics, Inc., HEALIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global cell therapy manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell therapy manufacturing market

Detailed Segmentation:

  • Global Cell Therapy Manufacturing Market, By Therapy Type:
    • Allogeneic Cell Therapy
    • Autologous Cell Therapy   
  • Global Cell Therapy Manufacturing Market, By Technology Type:
    • Somatic Cell Technology
    • Cell ImmortalizationTechnology
    • Viral Vector Technology
    • Genome Editing Technology
    • Cell Plasticity Technology
    • 3D Technology
  • Global Cell Therapy Manufacturing Market, By Source:
    • IPSC’s (Induced pluripotent stem cell)
    • Bone Marrow
    • Umbilical Cord
    • Adipose Tissue
    • Neural Stem
  • Global Cell Therapy Manufacturing Market, By Application:
    • Musculoskeletal
    • Cardiovascular
    • Gastrointestinal
    • Neurological
    • Oncology
    • Dermatology
    • Others
  • Global Cell Therapy Manufacturing Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • WuXi AppTec, Inc.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Lineage Cell Therapeutics, Inc.,
    • HEALIOS K.K.,
    • Lonza,
    • Merck KGaA.,
    • Takara Bio Inc.,
    • Sumitomo Dainippon Pharma Co., LTD.
    • Fujifilm Holdings Corporation
    • Thermo Fisher Scientific, Inc.
    • Astellas Pharma Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global cell therapy manufacturing market size is estimated to be valued at US$ 3,755.4 million in 2022 and is expected to exhibit a CAGR of 15.2% between 2022 and 2030.
Factors such as increasing collaborations by key market players, increasing development and launching various types of technologies for cell therapy manufacturing, increasing cell therapy based research and development are expected to drive the market.
Oncology is the leading application segment in the market.
The major factors hampering growth of the market include high cost of cell and gene therapies
Major players operating in the market include Wuxi AppTec, Inc, Lineage Cell Therapeutics, Inc., HEALIOS K.K., Lonza, Merck KGaA., Takara Bio Inc., Sumitomo Dainippon Pharma Co., LTD, Fujifilm Holdings Corporation, Thermo Fisher Scientific, Inc., Astellas Pharma Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo